Evidence map›Paper›PMID 40465706›Full record

ArticleScience advances2025

HDAC7 promotes renal cancer progression by reprogramming branched-chain amino acid metabolism.

Hyeyoung Nam, Anirban Kundu, Suman Karki, Richard L Kirkman, Darshan S Chandrashekar, Jeremy B Foote, Guofang Zhang, Wentao He, Sooryanarayana Varambally, Han-Fei Ding and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The histone deacetylase family in health and disease.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hyeyoung NamDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-9964-728X
Anirban KunduDepartment of Urology and the University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.ORCID 0000-0003-0621-9989
Suman KarkiDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-4393-4041
Richard L KirkmanDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-4212-0751
Darshan S ChandrashekarDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-4295-9127
Jeremy B FooteDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-6621-6096
Guofang ZhangSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.ORCID 0000-0003-3484-5864
Wentao HeSarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Sooryanarayana VaramballyDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-2277-1127
Han-Fei DingDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-5702-3439
Sunil SudarshanDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-7257-6277

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
RNA epigenetic regulation of cancer metabolismR01CA190429 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HAN-FEI DING · 2014 to 2026
$3.7M
Regulation of the Kidney Cancer Epigenome by Oncometabolite L-2-HydroxyglutarateR01CA200653 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SUNIL SUDARSHAN · 2016 to 2026
$3.6M
Linking nucleotide and amino acid metabolism to cholesterol synthesis by MYCNR01CA236890 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DING, HAN-FEI · 2020 to 2024
$1.7M
BLRD VA I01 BX002930NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA190429NCI NIH HHS R01 CA200653NCI NIH HHS R01 CA236890
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, exhibits notable metabolic reprogramming. We previously reported elevated HDAC7, a class II histone deacetylase, in ccRCC. Here, we demonstrate that HDAC7 promotes aggressive phenotypes and in vivo tumor progression in RCC. HDAC7 suppresses the expression of genes mediating branched-chain amino acid (BCAA) catabolism. Notably, lower expression of BCAA catabolism genes is strongly associated with worsened survival in ccRCC. Suppression of BCAA catabolism promotes expression of SNAIL1, a central mediator of aggressive phenotypes including migration and invasion. HDAC7-mediated suppression of the BCAA catabolic program promotes

Indexed as

Amino Acids, Branched-ChainCarcinoma, Renal CellHistone DeacetylasesKidney NeoplasmsAnimalsCell Line, TumorCell MovementDisease ProgressionGene Expression Regulation, NeoplasticHumansMiceSignal TransductionSnail Family Transcription FactorsAmino Acids, Branched-ChainHDAC7 protein, humanHistone DeacetylasesSNAI1 protein, humanSnail Family Transcription Factors

Identifiers

PMID40465706
PMCPMC12136004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.